Understand the source comparison
Difference Between Dihexa and P21: Research Comparison
The table below summarizes the key mechanistic, dosing, and application differences between Dihexa and P21 based on published research through 2026. Primary Mechanism HGF/c-Met receptor agonist promoting synaptogenesis and dendritic spine formation CNTF mimeti
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below summarizes the key mechanistic, dosing, and application differences between Dihexa and P21 based on published research through 2026.
- Primary Mechanism
- HGF/c-Met receptor agonist promoting synaptogenesis and dendritic spine formation
- CNTF mimetic activating JAK/STAT and MAPK pathways for neuronal survival and axonal growth
- Dihexa is synaptogenic; P21 is neuroprotective—distinct upstream targets
- Blood-Brain Barrier Penetration
- Passive diffusion (lipophilic small molecule)
- Limited (peptide structure); often uses intranasal delivery
- Dihexa achieves CNS concentrations more reliably via systemic routes
- Typical Dosing Range (Rodent)
- 0.5–5 mg/kg subcutaneous, once daily
- 1–10 mg/kg subcutaneous or intranasal, 1–2× daily
- Dihexa requires lower absolute doses; P21 often needs higher or more frequent dosing
- Half-Life
- ~2.5 hours (rodent plasma)
- Likely <30 minutes (peptide degradation)
- P21's shorter half-life necessitates more frequent administration
- Primary Research Applications
- Cognitive enhancement, age-related decline, TBI recovery, Alzheimer's models
- Stroke neuroprotection, oxidative stress, mitochondrial dysfunction, axonal injury
- Choose Dihexa for plasticity studies; P21 for acute neuroprotection
- Key Observable Outcome
- Increased synapse density, improved spatial memory performance
- Reduced neuronal apoptosis, decreased infarct volume post-injury
- Dihexa changes brain structure; P21 preserves neuronal viability